For example, class I FINs targeting SLC7A11, such as erastin and sulfasalazine (SAS), class II FINs targeting GPX4, such as RSL3 and ML162, and class III FINs depleting CoQ and GPX4, such as FIN56, could all sensitize non-small cell lung cancer cells to RT in vitro (Lei et al., 2020) (Fig. 4B). Here, GPX4 is linked to non-small cell lung carcinoma.